Oncternal Therapeutics Inc. is a clinical-stage oncology company. It is engaged in developing treatments for cancers with critical unmet medical need. The company's pipeline includes cirmtuzumab, TK-216 and CAR-T therapy that targets ROR1 which are in clinical stage. Oncternal Therapeutics Inc., formerly known as GTx Inc., is based in San Diego, California.
| Revenue (Most Recent Fiscal Year) | $0.79M |
| Net Income (Most Recent Fiscal Year) | $-39.48M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 29.27 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.84 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -5029.17% |
| Net Margin (Trailing 12 Months) | -5029.17% |
| Return on Equity (Trailing 12 Months) | -95.87% |
| Return on Assets (Trailing 12 Months) | -83.56% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.94 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.94 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $10.19 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-3.11 |
| Earnings per Share (Most Recent Fiscal Year) | $-13.43 |
| Diluted Earnings per Share (Trailing 12 Months) | $-13.51 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 2.69M |
| Free Float | 2.47M |
| Market Capitalization | $22.98M |
| Average Volume (Last 20 Days) | 6797.80 |
| Beta (Past 60 Months) | 1.26 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 16.05% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |